循環器ジャーナル65巻4号

2017年10月発行

特集 ACSの診断と治療はどこまで進歩したのか Ⅳ．ACSの二次予防

糖尿病治療

著者： 坂口一彦¹

所属機関： ¹神戸大学医学部附属病院総合内科学

ページ範囲：P.674 - P.683

Point
・糖尿病患者の心血管イベントや死亡の減少に，短期間の介入で効果のある薬剤が登場してきた．
・糖尿病治療の目的から考え，どの薬剤を用いて治療するかがこれからは重要になるかもしれない．

参考文献

1) 日本糖尿病学会編・著：糖尿病治療ガイド2016-2017，文光堂，2016

2) 中村二郎，神谷英紀，羽田勝計，他：—糖尿病の死因に関する委員会報告—アンケート調査による日本人糖尿病の死因—2001〜2010年の10年間，45,708名での検討—．糖尿病59:667-684, 2016

3) Ohkubo Y, Kishikawa H, Araki E, et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995

4) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993

5) Stratton IM, Adler AI, Neil HA, et al:Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes（UKPDS 35）:prospective observational study. BMJ 321:405-412, 2000

6) Action to Control Cardiovascular Risk in Diabetes Study Group:Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559, 2008

7) ADVANCE Collaborative Group:Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572, 2008

8) VADT Investigators:Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139, 2009

9) The ACCORD Study Group:Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care 39:701-708, 2016

10) ADVANCE-ON Collaborative Group:Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med 371:1392-1406, 2014

11) VADT Investigators:Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 372:2197-2206, 2015

12) Nissen SE, Wolski K:Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007

13) SAVOR-TIMI 53 Steering Committee and Investigators:Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 369:1317-1326, 2013

14) EXAMINE Investigators:Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med 369:1327-1335, 2013

15) TECOS Study Group:Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373:232-242, 2015

16) EMPA-REG OUTCOME Investigators:Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373:2117-2128, 2015

17) ELIXA Investigators:Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373:2247-2257, 2015

18) LEADER Steering Committee on behalf of the LEADER Trial Investigators:Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375:311-322, 2016

19) SUSTAIN-6 Investigators:Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New Engl J Med 375:1834-1844, 2016

20) Standl E, Schnell O, McGuire DK, et al:Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol 5:391-402, 2017